Pharmasum Therapeutics
Pharmasum Therapeutics is a private Norwegian pharmaceutical company focused on the discovery and development of novel drugs for treatment of neurological diseases, especially dementia. They are developing PST-674, a drug targeting DYRK1A enzyme, to address high unmet medical needs in dementia, including Alzheimer's disease, Parkinson's disease, and Down syndrome. The company aims to partner with major pharmaceutical companies for late-stage development and is engaged in advancing clinical trials and research in this field.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Development candidate: small-molecule DYRK1A inhibitor (lead compound)
An optimized small-molecule inhibitor of a disease-linked protein kinase developed through structure-guided design and medicinal chemistry, intended for treatment of dementia-related indications including Down syndrome–associated dementia, Alzheimer’s disease, and Parkinson’s-related dementia.
Development candidate: small-molecule DYRK1A inhibitor (lead compound)
An optimized small-molecule inhibitor of a disease-linked protein kinase developed through structure-guided design and medicinal chemistry, intended for treatment of dementia-related indications including Down syndrome–associated dementia, Alzheimer’s disease, and Parkinson’s-related dementia.
Services
Conduct of preclinical pharmacology programs including efficacy testing in animal models and PK evaluations.
Design and planning of Phase I tolerability studies and Phase 1b/2a proof-of-concept studies in genetically stratified patient populations, with pathway for later-stage partner-led trials.
Process development and scale-up of small-molecule synthesis and isolation of crystalline forms for development candidate compounds.
Regulatory planning and clinical program design supported by experienced regulatory leadership.
Conduct of preclinical pharmacology programs including efficacy testing in animal models and PK evaluations.
Design and planning of Phase I tolerability studies and Phase 1b/2a proof-of-concept studies in genetically stratified patient populations, with pathway for later-stage partner-led trials.
Process development and scale-up of small-molecule synthesis and isolation of crystalline forms for development candidate compounds.
Regulatory planning and clinical program design supported by experienced regulatory leadership.
Expertise Areas
- Neuroscience drug discovery
- Kinase inhibitor development
- Structure-based drug design
- Preclinical pharmacology and animal models
Key Technologies
- X-ray crystallography
- Structure-activity relationship (SAR) analysis
- Lead optimization medicinal chemistry
- Small-molecule kinase inhibition
News & Updates
Pharmasum reports successful scale-up and isolation of crystalline material of PST-674, with animal studies demonstrating robust pharmacokinetics, preparing for next development phases.
An article published in Frontiers in Pharmacology about the effects of DYRK1A inhibitor in Drosophila models of Alzheimer’s and Down syndrome.
An article published in Pharmaceuticals about the effects of Pharmasum's DYRK1A inhibitor in a mouse model of Down syndrome.
Pharmasum Therapeutics announced the nomination of DYRK1A protein kinase inhibitor PST-674 as the development candidate.
Pharmasum reports successful scale-up and isolation of crystalline material of PST-674, with animal studies demonstrating robust pharmacokinetics, preparing for next development phases.
An article published in Frontiers in Pharmacology about the effects of DYRK1A inhibitor in Drosophila models of Alzheimer’s and Down syndrome.
An article published in Pharmaceuticals about the effects of Pharmasum's DYRK1A inhibitor in a mouse model of Down syndrome.
Pharmasum Therapeutics announced the nomination of DYRK1A protein kinase inhibitor PST-674 as the development candidate.